
Please try another search
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a clinical stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on SGMO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that SGMO International could be a solid choice for investors.
Current Quarter Estimates for SGMO
In the past 30 days, two estimates have gone higher for Sangamo while none has gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 23 cents a share 30 days ago, to a loss of 18 cents a share today.
Current Year Estimates for SGMO
Meanwhile, Sangamo’s current year figures are also looking quite promising, with four estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 80 cents per share 30 days ago to a loss of 73 cents per share today.
Sangamo Therapeutics, Inc. Price and EPS Surprise
Bottom Line
The stock has also started to move higher lately, adding 24.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>
Nvidia’s earnings beat didn’t erase investor concerns over slowing growth. Soft Q1 guidance and valuation worries may limit the stock’s upside. Weak network and gaming sales...
Warren Buffett and Berkshire Hathaway (NYSE:BRKa) always make headlines in February when the firm holds its annual meeting. Among the many takeaways is what the company has been...
While Tuesday I wrote about the strength of junk bonds in the face of risk-off ratios (TLT v. SPY, HYG), today, I am still quite concerned about Granny Retail or the consumer...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.